Morgan Stanley analyst Carlos De Alba maintains Cleveland-Cliffs (NYSE:CLF) with a Equal-Weight and lowers the price target from $24 to $16.
FDA Approves Pharming’s Immune Disorder Drug, As First APDS Therapy
The FDA approved Pharming Group N.V.’s (NASDAQ:PHAR) Joenja (leniolisib) for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric…